The TROV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TROV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TROV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TROV Detailed Price Forecast - CNN Money||View TROV Detailed Summary - Google Finance|
|View TROV Detailed Summary - Yahoo! Finance||View TROV Stock Research & Analysis - Zacks.com|
|View TROV Trends & Analysis - Trade-Ideas||View TROV Major Holders - Barrons|
|View TROV Call Transcripts - NASDAQ||View TROV Breaking News & Analysis - Seeking Alpha|
|View TROV Annual Report - CompanySpotlight.com||View TROV OTC Short Report - OTCShortReport.com|
|View TROV Fundamentals - TradeKing||View TROV SEC Filings - Bar Chart|
|View Historical Prices for TROV - The WSJ||View Performance/Total Return for TROV - Morningstar|
|View the Analyst Estimates for TROV - MarketWatch||View the Earnings History for TROV - CNBC|
|View the TROV Earnings - StockMarketWatch||View TROV Buy or Sell Recommendations - MacroAxis|
|View the TROV Bullish Patterns - American Bulls||View TROV Short Pain Metrics - ShortPainBot.com|
|View TROV Stock Mentions - StockTwits||View TROV Stock Mentions - PennyStockTweets|
|View TROV Stock Mentions - Twitter||View TROV Investment Forum News - Investor Hub|
|View TROV Stock Mentions - Yahoo! Message Board||View TROV Stock Mentions - Seeking Alpha|
|View Insider Transactions for TROV - SECform4.com||View Insider Transactions for TROV - Insider Cow|
|View TROV Major Holdings Summary - CNBC||View Insider Disclosure for TROV - OTC Markets|
|View Insider Transactions for TROV - Yahoo! Finance||View Institutional Holdings for TROV - NASDAQ|
|View TROV Stock Insight & Charts - FinViz.com||View TROV Investment Charts - StockCharts.com|
|View TROV Stock Overview & Charts - BarChart||View TROV User Generated Charts - Trading View|
Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib
Posted on Tuesday December 11, 2018
As a result, new therapies are being developed in an effort to bring improved treatment options to patients, especially for some of the toughest-to-treat cancers. Trovagene caught my attention after the company released data from a Phase 1b/2 clinical trial of Onvansertib for the treatment of patients with Acute Myeloid Leukemia (AML). Through the ongoing Phase 1b segment of the trial, the company is working to identify the maximum-tolerated dose of Onvansertib in patients with AML who are ineligible for induction therapy or who have relapsed or refractory disease.
SAN DIEGO, Dec. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today presented updated data from its ongoing Phase 1b/2 study evaluating Onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML). The data, featured in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting, demonstrate that Onvansertib, in combination with LDAC or decitabine, even at the dose-escalation phase of the trial, is benefiting patients who have relapsed/refractory Acute Myeloid Leukemia (AML), and that the combination regimen is safe and well-tolerated, with no serious adverse events (SAEs) reported to-date.
What does TrovaGene Inc’s (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?
Posted on Wednesday November 21, 2018
TrovaGene Inc (NASDAQ:TROV), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is TROV will
Trovagene, Inc. Receives Positive Nasdaq Listing Decision
Posted on Thursday November 15, 2018
SAN DIEGO, Nov. 15, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions. The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 bid price requirement. "I am pleased that the Nasdaq Hearing Panel responded favorably," said Dr. Thomas Adams, Executive Chairman of Trovagene.